<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="timeframes is lacking. Viral infection Drug development timeframes Drug licensing" exact="United Kingdom" post="Strengths and limitations of this study This is the"/>
 <result pre="the Investigational New Drug (IND) Application (a step required by" exact="the US" post="Food and Drug Administration (FDA) prior to testing in"/>
 <result pre="the regulatory review process). For all new drugs approved in" exact="the USA" post="from 1992 to 2001, the authors found no increase"/>
 <result pre="filing (increasing from a mean 5.7 years for drugs approved in" exact="the USA" post="1980–1984, to 6.4 years for those approved 2005–2009) and concluded"/>
 <result pre="found by Kaitin and DiMasi for all drugs approved in" exact="the USA" post="between 1980 and 2009 (from 5.7 years in the period"/>
 <result pre="date of IND application, a process which only applies to" exact="the USA" post="and not to Europe. This point in the development"/>
 <result pre="decades the majority of new drugs have been launched in" exact="the USA" post="at an earlier or similar time to Europe.18 The"/>
 <result pre="and waiting periods21–24 and introduced a range of initiatives in" exact="the USA" post="and Europe to provide a more rapid pathway to"/>
</results>
